RUA Life Sciences plc, together with its subsidiaries, engages in the provision of polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates through Biomaterials, Contract Manufacture, Vascular, and Structural Heart segments. The Biomaterials segment operates as depository of the Intellectual Property and licensing rights to a range of biostable and implantable polymers, including Elast-Eon and ECSil. The Contract Manufacture segment provides sub-contract manufacturing, assembly, packing and services to the medical device. The Vascular segment develops bore polymer sealed grafts and soft tissue patches. The Structural Heart segment manufactures synthetic heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Ayrshire, the United Kingdom.

Rua Life Sciences PLC

Mr. William Donald Brown

Executive Chairman

Mr. Lachlan Arthur Smith

Rua Life Sciences PLC (RUA) Stock Analysis, Discussion Forum and Financial Metrics - LSE Exchange

Rua Life Sciences PLC (RUA) Earnings Report Date and History | LSE

RUA's next earnings is on December 16, 2024 (Before Market Open)

When is the earnings report for RUA?

RUA Earnings History

RUA Stock Discussion Forum and Message Board

News for LSE: RUA